News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
For the full year FY25, net profit soared 12x to Rs 345 crore
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Subscribe To Our Newsletter & Stay Updated
